Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel** is a non-product composite of six anticancer agents referenced across separate phase 2 treatment approaches for advanced non-small cell lung cancer. It is not a verified single co-formulated product or a documented regimen in which all six agents were administered together. In the cited analysis, carboplatin + gemcitabine followed by docetaxel, docetaxel + gefitinib, and carboplatin + paclitaxel + atrasentan were separate standard-therapy trial regimens that were pooled for comparison with ERCC1 and RRM1 expression-guided chemotherapy.
02
Targets
EDNRA (Endothelin receptor type A)RRM1EGFR (Epidermal growth factor receptor)DNAEDNRB (Endothelin receptor type B)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atrasentan + carboplatin + docetaxel + gefitinib + gemcitabine + paclitaxel.